Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Petmed Express ( (PETS) ) has shared an update.
On August 20, 2025, PetMed Express received a notice from Nasdaq due to a delay in filing its Annual and Quarterly Reports, leading to non-compliance with Nasdaq’s listing rules. The company has until September 1, 2025, to submit a compliance plan, and if accepted, it could have until December 29, 2025, to regain compliance. The notice does not immediately affect the company’s stock listing, and PetMed Express is working diligently to file the reports promptly.
The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
Spark’s Take on PETS Stock
According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.
Petmed Express shows a mixed financial performance with strong balance sheet stability but weak profitability and inconsistent cash flow. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics suggest the stock may be overvalued. The earnings call highlights progress in profitability and strategic investments, but challenges remain in sales and competitive pressures. Overall, the stock score reflects these combined factors, indicating moderate potential with significant risks.
To see Spark’s full report on PETS stock, click here.
More about Petmed Express
PetMed Express, Inc. operates in the pet pharmacy industry, providing prescription and non-prescription pet medications and other health products for dogs and cats directly to consumers. The company focuses on offering a convenient and cost-effective way for pet owners to obtain pet medications.
Average Trading Volume: 143,344
Technical Sentiment Signal: Sell
Current Market Cap: $64.86M
See more insights into PETS stock on TipRanks’ Stock Analysis page.